First Time Loading...

Seelos Therapeutics Inc
NASDAQ:SEEL

Watchlist Manager
Seelos Therapeutics Inc Logo
Seelos Therapeutics Inc
NASDAQ:SEEL
Watchlist
Price: 0.3 USD 7.53% Market Closed
Updated: May 2, 2024

Intrinsic Value

SEEL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]

The intrinsic value of one SEEL stock under the Base Case scenario is 0.4 USD. Compared to the current market price of 0.3 USD, Seelos Therapeutics Inc is Undervalued by 24%.

Key Points:
SEEL Intrinsic Value
Base Case
0.4 USD
Undervaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Seelos Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SEEL stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Seelos Therapeutics Inc

Provide an overview of the primary business activities
of Seelos Therapeutics Inc.

What unique competitive advantages
does Seelos Therapeutics Inc hold over its rivals?

What risks and challenges
does Seelos Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Seelos Therapeutics Inc recently?

Summarize the latest earnings call
of Seelos Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Seelos Therapeutics Inc.

Provide P/S
for Seelos Therapeutics Inc.

Provide P/E
for Seelos Therapeutics Inc.

Provide P/OCF
for Seelos Therapeutics Inc.

Provide P/FCFE
for Seelos Therapeutics Inc.

Provide P/B
for Seelos Therapeutics Inc.

Provide EV/S
for Seelos Therapeutics Inc.

Provide EV/GP
for Seelos Therapeutics Inc.

Provide EV/EBITDA
for Seelos Therapeutics Inc.

Provide EV/EBIT
for Seelos Therapeutics Inc.

Provide EV/OCF
for Seelos Therapeutics Inc.

Provide EV/FCFF
for Seelos Therapeutics Inc.

Provide EV/IC
for Seelos Therapeutics Inc.

Show me price targets
for Seelos Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Seelos Therapeutics Inc?

How accurate were the past Revenue estimates
for Seelos Therapeutics Inc?

What are the Net Income projections
for Seelos Therapeutics Inc?

How accurate were the past Net Income estimates
for Seelos Therapeutics Inc?

What are the EPS projections
for Seelos Therapeutics Inc?

How accurate were the past EPS estimates
for Seelos Therapeutics Inc?

What are the EBIT projections
for Seelos Therapeutics Inc?

How accurate were the past EBIT estimates
for Seelos Therapeutics Inc?

Compare the revenue forecasts
for Seelos Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Seelos Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Seelos Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Seelos Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Seelos Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Seelos Therapeutics Inc with its peers.

Analyze the financial leverage
of Seelos Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Seelos Therapeutics Inc.

Provide ROE
for Seelos Therapeutics Inc.

Provide ROA
for Seelos Therapeutics Inc.

Provide ROIC
for Seelos Therapeutics Inc.

Provide ROCE
for Seelos Therapeutics Inc.

Provide Gross Margin
for Seelos Therapeutics Inc.

Provide Operating Margin
for Seelos Therapeutics Inc.

Provide Net Margin
for Seelos Therapeutics Inc.

Provide FCF Margin
for Seelos Therapeutics Inc.

Show all solvency ratios
for Seelos Therapeutics Inc.

Provide D/E Ratio
for Seelos Therapeutics Inc.

Provide D/A Ratio
for Seelos Therapeutics Inc.

Provide Interest Coverage Ratio
for Seelos Therapeutics Inc.

Provide Altman Z-Score Ratio
for Seelos Therapeutics Inc.

Provide Quick Ratio
for Seelos Therapeutics Inc.

Provide Current Ratio
for Seelos Therapeutics Inc.

Provide Cash Ratio
for Seelos Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Seelos Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Seelos Therapeutics Inc?

What is the current Free Cash Flow
of Seelos Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Seelos Therapeutics Inc.

Financials

Balance Sheet Decomposition
Seelos Therapeutics Inc

Current Assets 5.4m
Cash & Short-Term Investments 3m
Receivables 763k
Other Current Assets 1.6m
Non-Current Assets 15k
PP&E 15k
Current Liabilities 38.9m
Accounts Payable 16.4m
Accrued Liabilities 2.5m
Other Current Liabilities 20m
Efficiency

Earnings Waterfall
Seelos Therapeutics Inc

Revenue
2.2m USD
Operating Expenses
-42.7m USD
Operating Income
-40.5m USD
Other Expenses
2.6m USD
Net Income
-37.9m USD

Free Cash Flow Analysis
Seelos Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

SEEL Profitability Score
Profitability Due Diligence

Seelos Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROE
Exceptional ROIC
ROE is Increasing
45/100
Profitability
Score

Seelos Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

SEEL Solvency Score
Solvency Due Diligence

Seelos Therapeutics Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
22/100
Solvency
Score

Seelos Therapeutics Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SEEL Price Targets Summary
Seelos Therapeutics Inc

There are no price targets for SEEL.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SEEL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SEEL Price
Seelos Therapeutics Inc

1M 1M
-46%
6M 6M
-94%
1Y 1Y
-99%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.3
52w Low
0.279
52w High
49.2
Price Metrics
Average Annual Return -22.08%
Standard Deviation of Annual Returns 40.31%
Max Drawdown -100%
Shares Statistics
Market Capitalization 4.1m USD
Shares Outstanding 13 680 600
Percentage of Shares Shorted 5.11%

SEEL Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Seelos Therapeutics Inc Logo
Seelos Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

4.1m USD

Dividend Yield

0%

Description

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The firm is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The firm's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. The company is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The firm's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.

Contact

NEW YORK
New York City
300 Park Avenue, 2Nd Floor
+16462932100.0
https://seelostherapeutics.com/

IPO

1993-10-27

Employees

15

Officers

Founder, Chairman, CEO & President
Dr. Raj Mehra J.D., Ph.D.
Chief Financial Officer
Mr. Michael J. Golembiewski
Senior Director of Clinical Development & Operations
Ms. Kimberly Farrand
Chief Communications Officer
Mr. Anthony Marciano
Head of Manufacturing & Technical Operations
Gopal Krishna Ph.D.
Chief Medical Officer
Tim Whitaker M.D.
Show More
Senior VP & Head of Clinical Operations
Ms. Karen Fusaro
Show Less

See Also

Discover More
What is the Intrinsic Value of one SEEL stock?

The intrinsic value of one SEEL stock under the Base Case scenario is 0.4 USD.

Is SEEL stock undervalued or overvalued?

Compared to the current market price of 0.3 USD, Seelos Therapeutics Inc is Undervalued by 24%.